Eric A. Collisson

2.1k total citations · 2 hit papers
15 papers, 1.0k citations indexed

About

Eric A. Collisson is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Eric A. Collisson has authored 15 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Cancer Research and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Eric A. Collisson's work include Pancreatic and Hepatic Oncology Research (11 papers), Cancer Genomics and Diagnostics (9 papers) and Renal cell carcinoma treatment (3 papers). Eric A. Collisson is often cited by papers focused on Pancreatic and Hepatic Oncology Research (11 papers), Cancer Genomics and Diagnostics (9 papers) and Renal cell carcinoma treatment (3 papers). Eric A. Collisson collaborates with scholars based in United States, Australia and South Africa. Eric A. Collisson's co-authors include Andrew V. Biankin, David K. Chang, Peter J. Bailey, Eileen M. O’Reilly, Wendy L. Frankel, Spencer C. Behr, Qian Shi, Robert Marsh, James L. Leenstra and Joseph M. Herman and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and European Journal of Cancer.

In The Last Decade

Eric A. Collisson

14 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular subtypes of pancreatic cancer

2019 530 citations Eric A. Collisson, Peter J. Bailey et al. Nature Reviews Gastroenterology & Hepatology profile →
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas

2022 144 citations Matthew H. G. Katz, Qian Shi et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric A. Collisson United States	7	839	443	309	289	166	15	1.0k
Yayun Zhu China	13	473 0.6×	291 0.7×	233 0.8×	217 0.8×	130 0.8×	22	744
Weikai Xiao China	18	477 0.6×	473 1.1×	265 0.9×	425 1.5×	114 0.7×	37	1.1k
Muhammad A. Khattak Australia	19	848 1.0×	505 1.1×	276 0.9×	389 1.3×	123 0.7×	44	1.2k
Traian Dumitraşcu Romania	14	777 0.9×	199 0.4×	360 1.2×	337 1.2×	452 2.7×	79	1.1k
J.M.G.H. van Riel Netherlands	14	720 0.9×	382 0.9×	415 1.3×	199 0.7×	98 0.6×	25	989
Jaykumar Thumar United States	10	480 0.6×	189 0.4×	147 0.5×	233 0.8×	125 0.8×	16	743
Haiqing Ma China	17	425 0.5×	321 0.7×	211 0.7×	511 1.8×	69 0.4×	27	965
Xuezhi Hao China	21	733 0.9×	216 0.5×	690 2.2×	372 1.3×	64 0.4×	114	1.1k
Hidenobu Ishii Japan	15	1.0k 1.2×	217 0.5×	692 2.2×	166 0.6×	74 0.4×	55	1.3k
Raymond Wadlow United States	14	485 0.6×	196 0.4×	179 0.6×	484 1.7×	79 0.5×	36	944

Countries citing papers authored by Eric A. Collisson

Since Specialization

Citations

This map shows the geographic impact of Eric A. Collisson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric A. Collisson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric A. Collisson more than expected).

Fields of papers citing papers by Eric A. Collisson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric A. Collisson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric A. Collisson. The network helps show where Eric A. Collisson may publish in the future.

Co-authorship network of co-authors of Eric A. Collisson

This figure shows the co-authorship network connecting the top 25 collaborators of Eric A. Collisson. A scholar is included among the top collaborators of Eric A. Collisson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric A. Collisson. Eric A. Collisson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Fergus, Kirkpatrick B., Justin Y. Newberg, Laura Fejerman, et al.. (2025). Association between ancestry and tumor somatic mutations in a large national cohort of women with breast cancer. npj Breast Cancer. 11(1). 117–117.

Tsang, Erica S., Scott Thomas, Jennifer A. Grabowsky, et al.. (2024). Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2. JCO Precision Oncology. 8(8). e2300494–e2300494. 1 indexed citations

Zack, Travis, Madhumita Sushil, Brenda Y. Miao, et al.. (2024). Assessing Large Language Models for Oncology Data Inference From Radiology Reports. JCO Clinical Cancer Informatics. 8(8). e2400126–e2400126. 4 indexed citations

Seepo, Sara, Divya Sain, Jack DiGiovanna, et al.. (2024). Pancreatic Cancer Action Network's SPARK: A Cloud-Based Patient Health Data and Analytics Platform for Pancreatic Cancer. JCO Clinical Cancer Informatics. 8(8). e2300119–e2300119. 4 indexed citations

Abuzeid, Waleed M., Brent K. Larson, Christos Fountzilas, et al.. (2023). Development of artificial intelligence–derived histological biomarkers for first-line treatment selection in metastatic pancreatic ductal adenocarcinoma (mPDAC).. Journal of Clinical Oncology. 41(4_suppl). 743–743. 2 indexed citations

Katz, Matthew H. G., Qian Shi, Joseph M. Herman, et al.. (2022). Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas. JAMA Oncology. 8(9). 1263–1263. 144 indexed citations breakdown →

Picozzi, Vincent J., Anne‐Marie Duliège, Eric A. Collisson, et al.. (2022). Precision Promise (PrP): An adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. 40(16_suppl). TPS4188–TPS4188. 6 indexed citations

Walker, Evan J., Amie Blanco, Julia Carnevale, et al.. (2022). The Additional Diagnostic Benefit of Pancreatic Cancer Molecular Profiling After Germline Testing. Pancreas. 51(4). 302–304. 3 indexed citations

Song, Zeyuan, Eric A. Collisson, Edith P. Mitchell, et al.. (2022). Phase II study of sunitinib in tumors with c-KIT mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol V. European Journal of Cancer. 174. S86–S86. 2 indexed citations

10.

Lawrence, Gabriella, et al.. (2022). Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. JAMA Network Open. 5(6). e2216199–e2216199. 47 indexed citations

11.

Hendifar, Andrew, Edik M. Blais, Brian M. Wolpin, et al.. (2021). Retrospective Case Series Analysis ofRAFFamily Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. JCO Precision Oncology. 5(5). 1325–1338. 22 indexed citations

12.

Katz, Matthew H. G., Qian Shi, Jeffrey P. Meyers, et al.. (2021). Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas.. Journal of Clinical Oncology. 39(3_suppl). 377–377. 100 indexed citations

13.

Collisson, Eric A., Peter J. Bailey, David K. Chang, & Andrew V. Biankin. (2019). Molecular subtypes of pancreatic cancer. Nature Reviews Gastroenterology & Hepatology. 16(4). 207–220. 530 indexed citations breakdown →

14.

Katz, Matthew H. G., Fang‐Shu Ou, Joseph M. Herman, et al.. (2017). Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 17(1). 505–505. 136 indexed citations

15.

Collisson, Eric A. & Kenneth P. Olive. (2017). Pancreatic Cancer: Progress and Challenges in a Rapidly Moving Field. Cancer Research. 77(5). 1060–1062. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact